Ticker: EVO

Speaker #1 (AI Assigned): I would like to remind you that all participants have been listening only more than the conference is being recorded. The presentation will be followed by a Q&A session.

Speaker #1 (AI Assigned): You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast.

Speaker #1 (AI Assigned): At this time, it is my pleasure to hand over to Sara Faki, Head of Corporate Communication and IR, please go ahead.

Speaker #2 (AI Assigned): Thank you, Sandra. Good morning, good afternoon, and welcome to today's webcast and conference call. My name is Sara Faki, and I'm the Head of Corporate Communications and Investor Relations at Evotec.

Speaker #2 (AI Assigned): Please allow me to introduce today's speakers. Joining me on the call are Christian Wojczewski, Chief Executive Officer of Evotec, and Claire Hinchelwood, our Chief Financial Officer.

Speaker #2 (AI Assigned): Please note that this call is being webcast live and will be archived in the event calendar on our website. Before we begin, a few forward-looking statements.

Speaker #2 (AI Assigned): The discussion and responses to your questions on this call reflect management's view, as of today, Thursday, November 5, 2026. During this call, we will make statements and provide responses that state our intentions, beliefs, expectations, or projections regarding the future.

Speaker #2 (AI Assigned): These statements constitute forward-looking statements within the meaning of applicable securities laws. They are subject to risks and uncertainties and actual results may differ materially from those expressed or implied.

Speaker #2 (AI Assigned): Evotec disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. For further information regarding these risks and uncertainties, please refer to our public filings and disclosures.

Speaker #2 (AI Assigned): With this, let me hand over the call to Christian.

Speaker #3 (AI Assigned): Thank you, Sara. Good morning and good afternoon to everyone. Thank you for joining today's call. The third quarter of 2026 showed encouraging progress after a challenging first half.

Speaker #3 (AI Assigned): We're beginning to see the different pieces of our transformation come together, and translate into improved business performance. Group revenues in Q3 were above both Q1 and Q2, mainly driven by stronger commercial execution in the DMPD-based business.

Speaker #3 (AI Assigned): At the same time, lower costs brought adjusted group EBITDA close to break even. The nine-month results still reflect the weaker first half, including slower sales-to-revenue conversion in DMPD and the Sandoz license contribution and GAAP in the first quarter of 2025.

Speaker #3 (AI Assigned): Our commercial ramp-up in DMPD is gaining traction. Net sales in the base business were up 24% for the first nine months, year over year.

Speaker #3 (AI Assigned): In this shorter cycle, business we're now beginning to see stronger commercial activity convert into revenue growth. In just Evotec Biologics, we're excited to confirm that Vertex Pharmaceuticals has selected us for the commercial manufacturing of Povitacept at our GPOT Redmond facility.

Speaker #3 (AI Assigned): This is an important step for GAAP as we advance our continuous manufacturing platform toward commercial scale readiness. Alongside this progress, Verizon execution is well on track.

Speaker #3 (AI Assigned): Our target is to deliver approximately 75 million euros in annual run rate savings by the end of 2027. For this year, we plan to deliver 20 to 30% of this target.

Speaker #3 (AI Assigned): By the end of September, we had already delivered more than 20% of the target, putting us ahead of plan. Footprint consolidation and workforce measures are starting to deliver tangible savings, while our focus on utilization and operational efficiency is supporting improved profitability.

Speaker #3 (AI Assigned): These developments give us greater confidence in the direction of the business. We reaffirm our full-year 2026 guidance and, based on our current visibility, expect revenue and adjusted EBITDA to land toward the upper end of their respective ranges.

Speaker #3 (AI Assigned): Later in the call, we will provide greater detail on our mid-range framework through 2030. This will give you better visibility into the business and a clearer view of the path forward, including how we expect the business mix to evolve and support a structurally stronger earnings profile.

Speaker #3 (AI Assigned): But before we move into the detailed review of the third quarter and first nine months, I'd like to highlight an important transition in our scientific leadership.

Speaker #3 (AI Assigned): Science is at the core of Evotec. And I'm therefore very pleased to introduce Dr. Joanna Holbrook. Joanna joined Evotec as Chief Scientific Officer and Member of the Management Board on November 1.

Speaker #3 (AI Assigned): She succeeded Cord Dohrmann, who left Evotec at the end of September. I'd like to take the opportunity to thank Cord for his many contributions over more than 16 years.

Speaker #3 (AI Assigned): He played an important role in building the scientific capabilities and innovation culture Evotec is known for. We're excited to have attracted a scientific leader of Joanna's caliber to Evotec.

Speaker #3 (AI Assigned): Joanna brings more than 25 years of international experience across pharma, biotech, and academia. Most recently, she held senior scientific leadership roles at Novo Nordisk. Previously, she served as Chief Scientific Officer at Biomodal.

Speaker #3 (AI Assigned): Joanna combines deep scientific expertise with a strong track record in applying new technologies and data-driven approaches to drug discovery and development. Her experience across different scientific environments organizational structures and cultures adds a broad perspective that will be particularly valuable as we continue to evolve Evotec.

Speaker #3 (AI Assigned): As Chief Scientific Officer, Joanna's focus will be clear. To strengthen our scientific profile, and translate advances in data science, AI, and novel technologies into greater value for customers and partners.

Speaker #3 (AI Assigned): On slide 6, let me continue with an overview of recent progress across selected partnerships. The most important development is in just Evotec Biologics, where we confirmed that Vertex Pharmaceuticals has selected GAAP for the commercial manufacturing of Povitacept Vertex investigational biologic candidate for a series kidney disease.

Speaker #3 (AI Assigned): Alongside this exciting progress, we're adding a third manufacturing train at our JPOT Redmond facility next year, expanding manufacturing capacity for the next phase of GAAP's growth.

Speaker #3 (AI Assigned): The additional capacity also positions us well to meet our manufacturing and supply commitments to Vertex. Furthermore, in our collaboration with the Department of War, GAAP advanced the Orthopox virus antibody program into a phase one clinical trial, having progressed the program from sequence to clinical supply.

Speaker #3 (AI Assigned): In DMPD, we continue to broaden our partnered innovation activities. The first candidate from our sleep disorder discovery collaboration with JAAS Pharmaceuticals has advanced into phase one clinical trial.

Speaker #3 (AI Assigned): Further, new and recent collaborations span next-generation therapeutic oncology approaches with Plaquetonic and AI-enabled drug discovery with Odyssey Therapeutics. Let me now hand the call over to Claire for a review of the Q3 and first nine months 2026 financials.

Speaker #2 (AI Assigned): Thank you, Christian, and good morning and good afternoon to everyone. Looking at our income statement on slide 7, group revenues for the third quarter of 2026 amounted to 164.9 million euros, broadly stable compared with 163.9 million euros in the prior year period.

Speaker #2 (AI Assigned): At constant exchange rates, Q3 group revenues amounted to €164.2 million, compared to €163.9 million in Q3 2025. The quarter benefited from stronger performance in the DMPD-based business, with improvement particularly visible in discovery and Cipratex.

Speaker #2 (AI Assigned): This helped offset continued timing and conversion effects in other segments. For the first nine months, group revenues totaled 465 million euros, reflecting a 13.1% decrease year on year from 535.1 million euros.

Speaker #2 (AI Assigned): At constant exchange rates, group revenues declined by 10.8% to 477.4 million euros, compared with 535.1 million euros in 2025. The nine-month comparison reflects a weaker first half of the year.

Speaker #2 (AI Assigned): DMPD remained affected by the slower sales-to-revenue conversion, while GAAP was impacted by delayed program activities and the 25 million dollar Sandoz license sale recognized in Q1 2025.

Speaker #2 (AI Assigned): Looking at the segments, DMPD revenues in Q3 were 120.1 million euros, down only 2.3% or 2.8 million euros from 122.9 million euros in the prior year quarter.

Speaker #2 (AI Assigned): At constant currencies, DMPD revenues totaled 119.6 million euros. For the first nine months, DMPD generated 348 million euros, representing an 11.2% decrease from 391.9 million euros in the prior year period.

Speaker #2 (AI Assigned): At constant exchange rates, DMPD revenues amounted to 355.5 million euros. Just Evotec Biologics delivered Q3 revenues of 44.8 million euros, an increase of 9.4% from 41 million euros in the prior year quarter.

Speaker #2 (AI Assigned): At constant exchange rates, revenues amounted to €44.6 million. For the first nine months, GAAP revenue totaled €117.1 million, representing an 18.2% decrease from €143.2 million in 2025.

Speaker #2 (AI Assigned): The year-on-year decrease was primarily driven by the non-recurring Sandoz license sale last year, and delayed program activities. At constant exchange rates, revenues amounted to 121.9 million euros.

Speaker #2 (AI Assigned): R&D expenses decreased to €29.7 million in the first nine months, or 6.4% of group revenue, compared with €42.3 million, or 7.9%, in the prior year period.

Speaker #2 (AI Assigned): Turning to profitability, adjusted group EBITDA improved significantly, in Q3 to minus 1.6 million euros from minus 15 million euros in the prior year quarter.

Speaker #2 (AI Assigned): Bringing the group close to break-even. The improvement was broad-based, with significantly better Q3 adjusted EBITDA performance in both DMPD and GAAP, supported by improved revenue contribution and a lower cost base.

Speaker #2 (AI Assigned): At constant exchange rates, adjusted EBITDA was minus 1.7 million euros. For the first nine months, adjusted group EBITDA decreased to minus 44.3 million euros from minus 16.9 million euros in 2025.

Speaker #2 (AI Assigned): The result primarily reflects the lower nine-month revenue base, partially offset by lower cost of revenues. At constant exchange rates, adjusted EBITDA was minus €39.1 million.

Speaker #2 (AI Assigned): At segment level, DMPD adjusted EBITDA improved to minus 1 million euros in Q3 from minus 9.5 million euros in the prior year quarter. At constant exchange rates, adjusted EBITDA amounted to minus 1.4 million euros.

Speaker #2 (AI Assigned): DMPD adjusted EBITDA for the first nine months, decreased to minus 25.5 million euros, compared with minus 18.8 million euros in the first nine months of 2025.

Speaker #2 (AI Assigned): GAAP adjusted EBITDA also improved significantly in the third quarter to minus 0.6 million euros from minus 5.5 million euros in Q3 2025. At constant exchange rates, adjusted EBITDA totaled minus 0.3 million euros.

Speaker #2 (AI Assigned): For the first nine months, adjusted EBITDA was minus 18.8 million euros in 2026, compared with plus 1.9 million euros in the prior year period, which included the Sandoz license sale.

Speaker #2 (AI Assigned): At constant exchange rates, nine-month adjusted EBITDA totaled 19.3 million euros. Turning to liquidity under balance sheet on slide 8, total liquidity as of September 30, 2026, stood at 401 million euros, representing a quarterly decrease of 65 million euros, compared with 466 million euros at the end of the second quarter of 2026.

Speaker #2 (AI Assigned): We continue to operate from a solid balance sheet. Looking ahead, rigorous cash flow management remains a key priority. With a continued focus on optimizing working capital, and preserving the optionality in our liquidity structure.

Speaker #2 (AI Assigned): Our capital discipline is reflected in the substantial reduction in capex from the elevated levels of recent years, which we reduced to our goal of under 10% of revenue.

Speaker #2 (AI Assigned): This demonstrates our selective investment approach, focusing on areas where we see the strongest strategic relevance and value creation potential, while continuing the shift towards the more capital-efficient operating model established under Horizon.

Speaker #2 (AI Assigned): One area of selective high-value investment in 2027 will be just Evotec Biologics. As already mentioned, we are investing in a third manufacturing train as part of the next phase of growth under J.

Speaker #2 (AI Assigned): Podge Redmond facility. Initial capex has already been incurred in 2026, with the remainder of the investment expected in 2027. That said, we expect capex for 2027 to remain broadly in line with 2026.

Speaker #2 (AI Assigned): Within that envelope, the third train will represent our largest individual investment next year. The investment will expand our manufacturing capacity, while benefiting from the lower capital-intensity of our continuous manufacturing technology.

Speaker #2 (AI Assigned): The installation will require a planned temporary pause in manufacturing activity at Redmond. The associated near-term impact on 27 manufacturing revenues is already reflected within our mid-range plan, which Christian will discuss later in this presentation.

Speaker #2 (AI Assigned): And with that, let me hand the call back to Christian.

Speaker #1 (AI Assigned): Thank you, Claire. Turning to commercial execution over the past several quarters, we have shared leading commercial indicators to provide greater visibility into the development of our DMPD business.

Speaker #1 (AI Assigned): As shown on slide 9, these indicators continued to strengthen the first nine months of 2026. In the DMPD base business, comprising standalone and integrated programs, net sales increased by 24% year-on-year, exceeding the respective prior year period in each of the first three quarters of 2026.

Speaker #1 (AI Assigned): The number of inbound leads increased by more than 45%, while proposal activity remained well above prior year levels, and proposal turnaround time improved by approximately 20%.

Speaker #1 (AI Assigned): Our DMPD customer base also increased by approximately 10%, compared with the first nine months of 2025. Importantly, we're now beginning to see stronger commercial activity translate into revenue in the shorter cycle-based business.

Speaker #1 (AI Assigned): Net sales generated during the first half are beginning to convert, with the Q3 revenue improvement particularly visible in discovery and supertax. We're also seeing a healthy pipeline of new strategic partnership opportunities, around 20 opportunities currently represent approximately 1 billion euro in total potential deal value.

Speaker #1 (AI Assigned): Our priority now is clear: maintain this momentum and translate it into sustainable growth. Turning to Horizon on slide 10, the transformation is making strong progress and remains ahead of plan.

Speaker #1 (AI Assigned): The structural measures are increasingly translating into tangible financial and operational results. Let me start with the financial impact. Our target is approximately 75 million euro in run-rate savings by the end of 2027.

Speaker #1 (AI Assigned): For 2026, we plan to deliver 20% to 30% of that target. By the end of September, Horizon had already delivered more than 20%, putting us ahead of plan.

Speaker #1 (AI Assigned): These savings are visible across our cost base, including COGS and SG&A. Approximately half of the announced workforce reductions have been implemented. Representing around 400 of the planned 800 positions.

Speaker #1 (AI Assigned): At the same time, footprint consolidation is on track. We expect three of the four planned site closures to be completed by year-end, with a fourth to follow in the first quarter of 2027.

Speaker #1 (AI Assigned): Alongside these efficiency measures, we continue to reshape our scientific footprint around fewer more focused areas of scientific excellence. The consolidation and transfer of capabilities across omics infectious diseases and protein science are well underway.

Speaker #1 (AI Assigned): Horizon is moving from implementation into tangible delivery, and we remain on track to deliver the full structural benefit of the program by the end of 2027.

Speaker #1 (AI Assigned): Moving from our Q3 and first nine months 2026 perspective, to our full year outlook. On slide 11, we are reaffirming the guidance we've provided on July 13, 2026.

Speaker #1 (AI Assigned): We expect group revenues in the range of €570 to €610 million on a reported basis, and €595 to €635 million at constant exchange rates.

Speaker #1 (AI Assigned): Adjusted group EBITDA is expected to land between minus 105 and minus 70 million euros, or between minus 90 and minus 60 million euros at constant exchange rates.

Speaker #1 (AI Assigned): Based on our performance through the first nine months, and our current visibility for the remainder of the year, we expect both revenue and adjusted EBITDA to finish toward the upper end of their respective guidance ranges.

Speaker #1 (AI Assigned): This reflects the improved performance we saw in the third quarter, while the assumptions underlying our July guidance update remain unchanged. Let me now zoom out one step further and, on slide 12, turn to our mid-range framework through 2030, which refers to what was announced in March this year.

Speaker #1 (AI Assigned): Our ambition is to generate around 1 billion euros in group revenues by 2030, with potential for additional upside. We further expect to achieve an adjusted EBITDA margin of 20% by the end of 2028, rising above 20% by the end of 2030.

Speaker #1 (AI Assigned): As announced in our webcast on July 14, going forward, we intend to provide greater transparency on how we expect to reach this ambition. In particular, we would like to provide a clearer view of our principal revenue streams and their underlying economics.

Speaker #1 (AI Assigned): The logic is similar across DMPD and GEP. Both segments have a base business, providing a growing and increasingly productive foundation. Additionally, both segments have revenue streams and profit pools, on top of their base businesses, derived from differentiated technology platforms and scientific innovation.

Speaker #1 (AI Assigned): In DMPD, the base business comprises our CRO services, including standalone and integrated programs. Here, we are serving end-to-end workflows across the full spectrum, from target identification to I&D.

Speaker #1 (AI Assigned): We expect this base business to contribute around 40% of revenue by 2030. Horizon and further productivity measures are expected to drive gross margin above 20%.

Speaker #1 (AI Assigned): On top of the base business, we will be extending our DMPD strategic partnership business. Those partnerships leverage our proprietary technology platforms and deep scientific expertise.

Speaker #1 (AI Assigned): They expect it to contribute another 20% of revenue by 2030 and offer attractive margin upside in excess of 15 percentage points, versus the base business through milestone payments and royalty contributions.

Speaker #1 (AI Assigned): Given the more volatile nature of this business, we have taken a risk-adjusted approach in our outlook, which also does not include future royalty income until 2030.

Speaker #1 (AI Assigned): Successful scientific execution of our existing long-term partnership commitments or new partnerships can provide milestones and royalty income beyond these assumptions. We intend to provide more granular insight into how the two components of the DMPD business develop, starting in 2027.

Speaker #1 (AI Assigned): In GEP, the base business is our CDMO offering, which is an engine for early and late-stage biologics. We've already demonstrated our ability to grow through our development in clinical manufacturing capabilities.

Speaker #1 (AI Assigned): Extension of our third train in Redmond and entering commercial manufacturing is expected to provide the basis for further growth. On top, licensing of our continuous manufacturing technology, including offerings such as JTrain, as scalable growth and higher margin income alongside partnership royalties.

Speaker #1 (AI Assigned): Overall, we expect the GEP business to contribute approximately 40% of revenue by 2030. The move into commercial manufacturing, together with the expansion of our licensing business, is expected to drive substantial margin expansion over time, with gross margin rising above 30%.

Speaker #1 (AI Assigned): Our 2030 ambition is about building a more balanced business with a structurally stronger earnings profile, and a more transparent path to sustainable profitability. On slide 13, let me provide an overview of the drivers behind the 40/20/40 revenue mix, and our 2030 mid-range framework.

Speaker #1 (AI Assigned): Starting with the DMPD base business, we expect revenues to reach approximately 400 million euros by 2030, representing a KGO of around 10%. Growth should be driven by the continued normalization and recovery of the early drug discovery market, stronger commercial execution, and our differentiated scientific and technology capabilities, including the increased contribution of AI to drug discovery and development.

Speaker #1 (AI Assigned): Strategic partnerships and innovation sit on top of this base, but follow a different trajectory. The blue line shown here reflects our risk-adjusted planning assumptions and reaches approximately 200 million euros by 2030, representing a KGO of around 5%.

Speaker #1 (AI Assigned): Given the volatile nature of this business, actual revenue development will not develop in a straight line. The timing and the progression of individual programs can result in periods above or below that trajectory, as illustrated by the wavy blue area around the risk-adjusted line.

Speaker #1 (AI Assigned): As discussed, the risk-adjusted trajectory deliberately takes a more balanced view, full scientific achievement or expansion of existing programs together with new strategic opportunities can provide additional upside.

Speaker #1 (AI Assigned): Just the Evotec Biologics has a different growth profile. Greater visibility on future demand, including our commercial manufacturing commitment with Vertex, has guided our decision to add a third manufacturing train at Redmond and expand capacity.

Speaker #1 (AI Assigned): As clearly discussed earlier, the installation will require a planned temporary pause in manufacturing activities in 2027, with a resulting near-term revenue impact already reflected in our plan.

Speaker #1 (AI Assigned): Once the additional capacity comes online, we expect growth to accelerate meaningfully. Higher utilization and increasing contributions from higher margin licensing income and future royalties are expected to drive revenue to approximately 400 million euros by 2030, representing a KGO of around 20%.

Speaker #1 (AI Assigned): Taken together, these differentiated contributions provide a clear path towards the more balanced, scalable, and profitable business, but targeting for 2030. Before we move on to the Q&A session, I would like to briefly summarize today's key takeaways on slide 14.

Speaker #1 (AI Assigned): The third quarter gives us encouraging evidence that the business is moving in the right direction. Commercial execution is strengthening, and in the DMPD base business, we're beginning to see stronger net sales translate into revenue.

Speaker #1 (AI Assigned): At the same time, improved profitability shows the impact of a lower cost base and better execution. Horizon is ahead of plan, savings are increasingly visible, structural measures are well advanced, and we expect to deliver the full program on time.

Speaker #1 (AI Assigned): In just Evotec Biologics, the Vertex agreement marks an important step toward commercial manufacturing. Together with our planned capacity expansion, this provides a stronger foundation for the next phase of GEP's growth.

Speaker #1 (AI Assigned): We confirm our 2026 guidance and expect revenue and adjusted EBITDA towards the upper end of their respective ranges. Looking beyond 2026, we have also given you greater transparency into the structure and economics of our business.

Speaker #1 (AI Assigned): The clear distinction between the DMPD business, DMPD base business, strategic partnerships, and GEP shows how different growth and margin profiles are expected to combine into a more balanced business and a structurally stronger earnings profile.

Speaker #1 (AI Assigned): To further improve understanding of our business, we plan to complement our regular reporting with selected virtual deep dives into key areas of the business over the coming months.

Speaker #1 (AI Assigned): Providing greater insight into the capabilities, growth drivers, and value potential. It's still work ahead, but the direction is clear: stronger commercial execution, a more efficient cost base, and a more attractive business mix.

Speaker #1 (AI Assigned): With this, I would like to close the call and welcome your questions. Thank you.

Speaker #2 (AI Assigned): We will now begin the question-and-answer session. Anyone who wishes to ask a question may press star and 1 on the telephone. You will hear a tone to confirm that you've entered the queue.

Speaker #2 (AI Assigned): If you wish to remove yourself from the question queue, you may press star and 2. Participants are requested to disable loudspeaker mode while asking a question.

Speaker #2 (AI Assigned): Anyone who has a question may press star and 1 at this time. Our first question comes from Charles Weston from RBC. Please go ahead.

Speaker #3 (AI Assigned): Hello. Thank you for taking the questions. Three, if I can. A near-term question first. Could you disclose what milestones strategic milestones you received in Q3 and what expectations might be for Q4?

Speaker #3 (AI Assigned): My longer-term question is around the JEB business. Specifically, what gives you the confidence that that business can more than double over the next well, up to 2030?

Speaker #3 (AI Assigned): Particularly in light of the Sando development revenues that will presumably have become quite small by then. And then my last one is more of a conceptual one.

Speaker #3 (AI Assigned): The current environment has got everyone very excited about AI. You've obviously been invested in the AI and data sets for a number of years.

Speaker #3 (AI Assigned): So, could you just give us some color on whether this positioning has led to any meaningful, tangible leads? Thank you.

Speaker #4 (AI Assigned): Thank you, Charles. And hello. And I'll start and see if Claire wants to chip in as well on the milestones. I understand you were talking about Q3 and Q4 this year, if I'm correct.

Speaker #3 (AI Assigned): That's right.

Speaker #4 (AI Assigned): Yeah, so not in a meaningful amount, but Claire will further allude to that. And then on the GEP topic, confidence about 2030 in light of Sandoz.

Speaker #4 (AI Assigned): Well, I think we try to explain that when you look at the Sandoz profile, there were short, mid-term, and long-term economic benefits of the deal.

Speaker #4 (AI Assigned): We're now in the mid-term phase, 2026 to 2028, where we are doing the joint development work. Thereafter, basically the 10 molecules coming to market, we're eligible to royalty payments.

Speaker #4 (AI Assigned): So that is obviously something that is going to contribute as of 2029, 2030. To a certain amount, not peak values, but to a certain amount, but I think we also just alluded to the fact that we've lined up new customers and we're also quite confident with regard to the being ready for Vertex which will obviously play an important role in our mid-range plan.

Speaker #4 (AI Assigned): On the AI positioning, absolutely. Charles, it's also a contributor to revenue growth that we've seen in parts of our cyber techs and discovery business.

Speaker #4 (AI Assigned): We're actually doing business and generating work and revenues with quite a few of the drug discovery companies that have focused on AI. And we expect this to further continue if not even accelerate.

Speaker #4 (AI Assigned): Claire, any further flavor on the milestone topic?

Speaker #5 (AI Assigned): Yeah. So on the milestones in the third quarter, Charles, those roundabout 30 million included, and we would expect that to be quite a bit less in the fourth quarter.

Speaker #4 (AI Assigned): devil is in the detail because it very much depends on the how long these projects then actually last, whether it's high velocity, short cycled business, or longer projects.

Speaker #4 (AI Assigned): But roughly when you think about this concept, then you probably will appreciate '25 being the trough. This certainly has impacted '26 revenues and will be washed out over time.

Speaker #4 (AI Assigned): And clearly that then indicates that it's reasonable to expect a rebound in the next couple of quarters also from a revenue perspective. When it comes to the BMS dynamic, we also explained that there was a substantial revenue decline between '23 to '26.

Speaker #4 (AI Assigned): The work orders have stabilized. We expect the BMS contribution to grow the next 12 to 24 months. So the '27 guidance, which we're then going to issue beginning of next year, will then reflect the latest view on phasing of revenues milestones and so forth.

Speaker #4 (AI Assigned): But it's fair to say that at this point in time, we see '25 as a trough with regard to net sales. And '26 actually the trough when it comes to revenues.

Speaker #4 (AI Assigned): Hope that helps.

Speaker #1 (AI Assigned): Yeah, very helpful. Thank you very much.

Speaker #3 (AI Assigned): As a reminder, if you wish to register for a question, please press star followed by one. Our next question comes from Brendan Smith from TD Cowen.

Speaker #3 (AI Assigned): Please go ahead.

Speaker #5 (AI Assigned): Hi, this is Jacqueline ine Onford's Brendan. I appreciate you taking the questions. Maybe just one from me on the AI side of the conversation.

Speaker #5 (AI Assigned): Have you seen any customer inquiries specifically around data generation? Given your numerous touchpoints across the discovery process, and are there any areas of white space you're thinking of expanding into with regards to your modeling development that could potentially further bolster those DMPD sales?

Speaker #4 (AI Assigned): Thanks for the question. Not just have we seen customer inquiries, but we are actually actively doing work with customers on this topic. Data generation is a big topic.

Speaker #4 (AI Assigned): As I mentioned, it can be related to chemical compound generation can be related to DMPK tox safety profiling. So many, many areas this is an important driver right now also for the positive sales dynamic that we're seeing.

Speaker #4 (AI Assigned): We are there's quite a bit that we haven't in-house already when it comes to data let me remind you, our molecular patient database as such, of high, high value and interest in the market because that's something that you cannot quickly generate and has been built over a decade at Evotech.

Speaker #4 (AI Assigned): So, this is a super strong asset in our minds and is attracting a lot of interest also from partners. The other part, obviously, when it comes to data generation, still a lot of demand is related to tox studies and helping to train models here.

Speaker #4 (AI Assigned): But this is not something far out. This is real business meanwhile.

Speaker #5 (AI Assigned): Great. Thank you.

Speaker #3 (AI Assigned): We have a follow-up question from Charles Weston from RBC. Please go ahead.

Speaker #6 (AI Assigned): Hi. Thanks for taking the follow-up. Just you've mentioned the word strategy a lot of times on this call, Christian. And you've been quite clear with strategic goals 2030, near-term strategy.

Speaker #6 (AI Assigned): But you're undergoing a strategic review as well. So I'm just wondering what aspects of a strategy are still left to be determined? Thank you.

Speaker #4 (AI Assigned): You're asking me to give my holding statement. The review is ongoing, Charles.

Speaker #6 (AI Assigned): It's worth it, guys. Thank you.

Speaker #3 (AI Assigned): Ladies and gentlemen, that was the last question. I would now like to turn the conference back over to Sarah Fakih for any closing remarks.

Speaker #7 (AI Assigned): Thank you. With this, we would like to conclude today's conference call. Thank you for your participation, and please feel free to reach out to the Investor Relations team should you have any further questions.

Speaker #7 (AI Assigned): Thank you and goodbye.

Speaker #3 (AI Assigned): Ladies and gentlemen, the conference is now over. Thank you for choosing Coruscal and thank you for participating in the conference. You may now disconnect your lines.

More EVO earnings call transcripts

Browse all earnings call transcripts

EVO Q3 2026 Earnings Call

Demo

EVO

Earnings

EVO Q3 2026 Earnings Call

EVO

Thursday, November 5th, 2026

Transcript

No Transcript Available

No transcript data is available for this event yet. Transcripts typically become available shortly after an earnings call ends.

Want AI-powered analysis? Try AllMind →

Earnings analysis guides

Methods for extracting KPIs and checking source support when reviewing an earnings call.

Browse all earnings calls